Dramatic change in prescribing of hormone replacement therapy in the Netherlands after publication of the Million Women Study: A follow-up study

British Journal of Clinical Pharmacology

Volumn 60, Issue 6, 2005, Pages 641-647

  Faber, Adrianne ^a   Bouvy, Marcel L ^b,c   Loskamp, Linda ^a   Van De Berg, Paul B ^a   Egberts, Toine C G ^c   De Jong Van Den Berg, Lolkje T W ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b SIR Institute for Pharmacy Practice and Policy   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Drug utilization; Hormone replacement therapy; Prescribing; Risk

Indexed keywords

CYPROTERONE; DIENOGEST; DYDROGESTERONE; ESTRADIOL; ESTRIOL; ESTROGEN; ETHINYLESTRADIOL; GESTAGEN; LEVONORGESTREL; LYNESTRENOL; MEDROGESTONE; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE ACETATE; NORGESTREL; TIBOLONE;

ADULT; AGED; ARTICLE; CONFIDENCE INTERVAL; DIFFUSION; FEMALE; FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; MEDICAL PRACTICE; OUTCOMES RESEARCH; PHARMACY; POSTMENOPAUSE; PRACTICE GUIDELINE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; PUBLICATION; SAFETY; TIME SERIES ANALYSIS;

AGE FACTORS; AGED; COMMUNITY PHARMACY SERVICES; CROSS-SECTIONAL STUDIES; DIFFUSION OF INNOVATION; DRUG UTILIZATION; ESTROGEN REPLACEMENT THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NETHERLANDS; PHYSICIAN'S PRACTICE PATTERNS; POSTMENOPAUSE; PRACTICE GUIDELINES; PRESCRIPTIONS, DRUG; SAFETY; WOMEN'S HEALTH;

EID: 28244434377     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2005.02502.x     Document Type: Article

References (22)

1. Writing group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results form the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33.
2. Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, Hendrix SL, Jones BN, Assaf AR, Jackson RD, Kotchen JM, Wassertheil-Smoller S, Wactawski-Wende J; WHIMS Investigators. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. The Women's Health Initiative Memory study: a randomized controlled trial. JAMA 2003; 289: 2651-62.
3. Writing group for the Women's Health Initiative Investigators. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA 2004; 291: 1701-12.
4. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419-27.
5. Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B, Speizer FE, Hennekens CH. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996; 335: 453-61.
6. Pan CX. Hormone replacement therapy for secondary prevention of coronary heart disease. JAMA 1999; 281: 794.
7. Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health 1998; 19: 55-72.
8. Dutch College of General Practitioners. http://nhg.artsennet.nl, accessed on 8 November 2004.
9. Dutch Society of Obstetrics and Gynaecology. Press release on website: http://www.nvog.nl, accessed on 8 November 2004.
10. Wilkinson JJ, Force RW, Cady PS. Impact of safety warnings on drug utilization: marketplace life span of cisapride and troglitazone. Pharmacotherapy 2004; 24: 978-86.
11. Maclure M, Dormuth C, Naumann T, McCormack J, Rangno Whiteside C, Wright JM. Influences of educational interventions and adverse news about calcium-channel blockers on first-line prescribing of antihypertensive drugs to elderly people in British Columbia. Lancet 1998; 352: 943-8.
12. Hersh AL, Ste MJ, Stafford RS. National use of postmenopausal hormone therapy. Annual trends and response to recent evidence. JAMA 2004; 291: 47-53.
13. Haas JS, Kaplan CP, Gerstenberger EP, Kerlikowske K. Changes in the use of postmenopausal hormone therapy after the publication of clinical trials results. Ann Intern Med 2004; 140: 184-8.
14. Lawton B, Rose S, McLeod D, Dowell A. Changes in use of hormone replacement therapy after the report from the Women's Health Initiative: cross sectional survey of users. BMJ 2003; 327: 845-6.
15. Tobi H, van den Berg PB, de Jong-van den Berg LTW. The Interaction Database: synergy of science and practice in pharmacy. In Medical Data Analysis, eds Brause RW, Hanisch E. Berlin: Springerverlag 2000; 206-11.
16. Schirm E, Monster TBM, de Vries R, van den Berg PB, de Jongvan den Berg LTW, Tobi H. How to estimate the population that is covered by community pharmacies? An evaluation of two methods using drug utilisation information. Pharmacoepidemiol Drug Saf 2004; 13: 173-9.
17. Leufkens HGM, Urquhart J. Automated pharmacy record linkage in the Netherlands. In Pharmacoepidemiology, 3rd edn, ed. Strom BL. Chichester: John Wiley & Sons Ltd. 2000; 347-60.
18. Tobi H, van den Berg PB, Brouwers JRBJ, de Jong-van den Berg LTW. Hormone replacement therapy in peri- and postmenopausal women: more than half use HRT longer than 1 year (in Dutch). Ned Tijdschr Geneeskd 2003; 147: 1853-5.
19. Keating NL, Clearly PD, Rossi AS, Zaslavsky AM, Aynian JZ. Use of hormone replacement therapy by postmenopausal women in the United States. Ann Intern Med 1999; 130: 545-53.
20. Lagro-Janssen T, Rosser WW, van Weel C. Breast cancer and hormone-replacement therapy: up to general practice to pick up the pieces. Lancet 2003; 362: 414-5 (Editorial).
21. Teichert M, de Smet PAGM. Hormone use during menopause [Hormoongebruik in de overgang]. Pharm Weekbl 2004; 139: 634-5.
22. Monster TBM, de Jong-van den Berg LTW. No longer place for long-term hormone replacement therapy [Geen plaats meer voor langdurige hormoonsubstitutie therapie]. Pharm Weekbl 2002; 137: 1132-4.